Pfizer (PFE)

With a history that can be traced all the way back to 1849, Pfizer is a mega-cap pharmaceutical and biotechnology company. The pandemic made it even more well-known globally.

Over 3.6 billion Pfizer-BioNTech COVID-19 vaccines have been shipped to 180 countries worldwide. Meanwhile, Pfizer is also the developer of Paxlovid, an oral antiviral pill used to treat COVID-19.

The company reported strong results this earnings season. For Q2, Pfizer generated $27.7 billion of revenue, representing a 47% increase year-over-year. Adjusted earnings per share came in at $2.04, up 92% from the year-ago period.

The stock, however, is not immune to the market sell-off in 2022. Year-to-date, Pfizer shares have slipped 12%.

JPMorgan analyst Chris Schott has a ‘neutral’ rating on Pfizer and a price target of $57 — roughly 15% above where the stock sits today.

Fine wine is a sweet comfort in any situation — and now it can make your investment portfolio a little more comfortable, too. Now a platform called Vinovest helps everyday buyers invest in fine wines — no sommelier certification required.

Invest Now

Gilead Sciences (GILD)

Gilead Sciences is another biopharmaceutical company that made headlines during the pandemic. It is the developer of Veklury (remdesivir), the first antiviral drug approved by the FDA for the treatment of COVID-19 requiring hospitalization.

The company reported Q2 earnings on Tuesday. For the quarter, revenue edged up 1% year-over-year to $6.3 billion. Adjusted earnings per share declined 13% year over year to $1.58.

While these numbers don’t look impressive on their own, they smashed Wall Street’s expectations. On average, analysts expected Gilead to report earnings of $1.52 per share on $5.86 billion of revenue for the quarter.

Management also boosted their guidance. For full-year 2022, they expect the company to earn $24.5 billion to $25 billion in total product sales, up from their previous guidance range of $23.8 billion to $24.3 billion.

The stock shot up 4.6% on Wednesday. However, it’s still down 14% year to date.

Piper Sandler analyst Do Kim recently reiterated a ‘neutral’ rating on Gilead while raising the price target from $69 to $71. Considering that Gilead trades at $62.27 today, the price target implies a potential upside of 14%.

Abbott Laboratories (ABT)

Abbott Laboratories is a healthcare company that specializes in medical devices, diagnostics, nutrition products, and branded generic medicines.

Like the other two companies, Abbott hasn’t been a hot ticker. Its shares have fallen a painful 21% in 2022.

But the company is solidly-positioned for another wave of COVID-19 – it makes COVID-19 testing kits.

According to the latest earnings report, COVID-19 testing-related sales amounted to $2.3 billion for Abbott in Q2 of 2022.

Sales totaled $11.3 billion for the quarter, representing a 10.1% increase year over year. Adjusted earnings per share grew 22.2% from a year ago to $1.43.

Management expects the company to earn $6.1 billion in COVID-19 testing-related sales in full-year 2022.

Citi analyst Joanne Wuensch has a ‘buy’ rating on Abbott and a price target of $123 — around 12% above the current levels.

Get a piece of commercial real estate

Enhance your portfolio with high-return commercial real estate

First National Realty Partners is the #1 option for accredited investors seeking superior risk-adjusted returns in the grocery-anchored necessity-based retail space.

While commercial real estate has always been reserved for a few elite investors, outperforming the S&P 500 over a 25-year period, First National Realty Partners allows you to access institutional-quality commercial real estate investments — without the leg work of finding deals yourself.

Invest with First National Realty Partners now.

About the Author

Jing Pan

Jing Pan

Investment Reporter

Jing is an investment reporter for MoneyWise. He is an avid advocate of investing for passive income. Despite the ups and downs he’s been through with the markets, Jing believes that you can generate a steadily increasing income stream by investing in high quality companies.

What to Read Next

Disclaimer

The content provided on MoneyWise is information to help users become financially literate. It is neither tax nor legal advice, is not intended to be relied upon as a forecast, research or investment advice, and is not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. Tax, investment and all other decisions should be made, as appropriate, only with guidance from a qualified professional. We make no representation or warranty of any kind, either express or implied, with respect to the data provided, the timeliness thereof, the results to be obtained by the use thereof or any other matter.